Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

732 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS. Robert C, et al. Among authors: ribas a. J Clin Oncol. 2018 Jun 10;36(17):1668-1674. doi: 10.1200/JCO.2017.75.6270. Epub 2017 Dec 28. J Clin Oncol. 2018. PMID: 29283791 Clinical Trial.
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J. Ribas A, et al. J Clin Oncol. 2005 Dec 10;23(35):8968-77. doi: 10.1200/JCO.2005.01.109. Epub 2005 Oct 3. J Clin Oncol. 2005. PMID: 16204013 Clinical Trial.
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A. Camacho LH, et al. Among authors: ribas a. J Clin Oncol. 2009 Mar 1;27(7):1075-81. doi: 10.1200/JCO.2008.19.2435. Epub 2009 Jan 12. J Clin Oncol. 2009. PMID: 19139427 Clinical Trial.
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J. Ribas A, et al. Clin Cancer Res. 2009 Oct 1;15(19):6267-76. doi: 10.1158/1078-0432.CCR-09-1254. Epub 2009 Sep 29. Clin Cancer Res. 2009. PMID: 19789309 Free PMC article. Clinical Trial.
Assessing oncologic benefit in clinical trials of immunotherapy agents.
Hales RK, Banchereau J, Ribas A, Tarhini AA, Weber JS, Fox BA, Drake CG. Hales RK, et al. Among authors: ribas a. Ann Oncol. 2010 Oct;21(10):1944-1951. doi: 10.1093/annonc/mdq048. Epub 2010 Mar 17. Ann Oncol. 2010. PMID: 20237004 Free article. Review.
Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma.
Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, Rodriguez MJ, Prieto VG, Glaspy JA, Oseguera DK, Hernandez J, Villanueva A, Chmielowski B, Mitsky P, Bercovici N, Wasserman E, Landais D, Ross MI. Ribas A, et al. J Transl Med. 2010 Sep 27;8:89. doi: 10.1186/1479-5876-8-89. J Transl Med. 2010. PMID: 20875102 Free PMC article. Clinical Trial.
732 results